Pharmacologic inhibition of vein graft neointimal hyperplasia

Journal of Thoracic and Cardiovascular Surgery

Volumn 131, Issue 5, 2006, Pages 1065-1072

  Schachner, Thomas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ACETYLSALICYLIC ACID; BOSENTAN; BSF 302146; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CGS 24592; CHYMASE INHIBITOR; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENZYME INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PERILLYL ALCOHOL; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; SPERMINE; SURAMIN; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DRUG ELUTING STENT; DRUG INHIBITION; GRAFT FAILURE; HEART CELL CULTURE; IN-STENT RESTENOSIS; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; SAPHENOUS VEIN; SHEAR STRESS; SMOOTH MUSCLE FIBER; VEIN GRAFT;

ANIMALS; ATHEROSCLEROSIS; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERPLASIA; THROMBOSIS; TUNICA INTIMA; VASCULAR PATENCY; VEINS;

EID: 33646192303     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2005.11.043     Document Type: Article

References (86)

1. Shah P.J., Gordon I., Fuller J., Seevanayagam S., Rosalion A., Tatoulis J., et al. Factors affecting saphenous vein graft patency. clinical and angiographic study in 1402 symptomatic patients operated on between 1977 and 1999. J Thorac Cardiovasc Surg 126 (2003) 1972-1977
2. Goldman S., Zadina K., Moritz T., Ovitt T., Sethi G., Copeland J.G., et al., VA Cooperative Study Group #207/297/364. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery. results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 44 (2004) 2149-2156
3. Arima M., Kanoh T., Suzuki T., Kuremoto K., Tanimoto K., Oigawa T., et al. Serial angiographic follow-up beyond 10 years after coronary artery bypass grafting. Circ J 69 (2005) 896-902
4. Dion R., Glineur D., Derouck D., Verhelst R., Noirhomme P., El Khoury G., et al. Complementary saphenous grafting. long-term follow-up. J Thorac Cardiovasc Surg 122 (2001) 296-304
5. Sabik J.F., Lytle B.W., Blackstone E.H., Houghtaling P.L., and Cosgrove D.M. Comparison of saphenous vein and internal thoracic artery graft patency by coronary system. Ann Thorac Surg 79 (2005) 544-551
6. Shah P.J., Bui K., Blackmore S., Gordon I., Hare D.L., Fuller J., et al. Has the in situ right internal thoracic artery been overlooked? An angiographic study of the radial artery, internal thoracic arteries and saphenous vein graft patencies in symptomatic patients. Eur J Cardiothorac Surg 27 (2005) 870-875
7. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease. pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
8. Shuhaiber J.H., Evans A.N., Massad M.G., and Geha A.S. Mechanisms and future directions for prevention of vein graft failure in coronary bypass surgery. Eur J Cardiothorac Surg 22 (2002) 387-396
9. Bonatti J., Oberhuber A., Schachner T., Zou Y., Hammerer-Lercher A., Mittermair R., et al. Neointimal hyperplasia in coronary vein grafts. pathophysiology and prevention of a significant clinical problem. Heart Surg Forum 7 (2004) 72-87
10. O'Brien J.E., Ormont M.L., Shi Y., Wang D., Zalewski A., and Mannion J.D. Early injury to the media after saphenous vein grafting. Ann Thorac Surg 65 (1998) 1273-1278
11. Rodriguez E., Lambert E.H., Magno M.G., and Mannion J.D. Contractile smooth muscle cell apoptosis early after saphenous vein grafting. Ann Thorac Surg. 70 (2000) 1145-1153
12. Zhang L., Freedman N.J., Brian L., and Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler Thromb Vasc Biol 24 (2004) 470-476
13. Fogelstrand P., Osterberg K., and Mattsson E. Reduced neointima in vein grafts following a blockage of cell recruitment from the vein and the surrounding tissue. Cardiovasc Res 67 (2005) 326-332
14. Hu Y., Mayr M., Metzler B., Erdel M., Davison F., and Xu Q. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res 91 (2002) e13-e20
15. Hu Y., Zhang Z., Torsney E., Afzal A.R., Davison F., Metzler B., et al. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. J Clin Invest 113 (2004) 1258-1265
16. Xu Q., Zhang Z., Davison F., and Hu Y. Circulating progenitor cells regenerate endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient mice. Circ Res 93 (2003) e76-e86
17. O'Brien J.E., Shi Y., Fard A., Bauer T., Zalewski A., and Mannion J.D. Wound healing around and within saphenous vein bypass grafts. J Thorac Cardiovasc Surg 114 (1997) 38-45
18. Shi Y., O'Brien J.E., Mannion J.D., Morrison R.C., Chung W., Fard A., et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 95 (1997) 2684-2693
19. Zou Y., Dietrich H., Hu Y., Metzler B., Wick G., and Xu Q. Mouse model of venous bypass graft arteriosclerosis. Am J Pathol 153 (1998) 1301-1310
20. Cross K.S., el-Sanadiki M.N., Murray J.J., Mikat E.M., McCann R.L., and Hagen P.O. Mast cell infiltration. a possible mechanism for vein graft vasospasm. Surgery 104 (1988) 171-177
21. Zou Y., Hu Y., Mayr M., Dietrich H., Wick G., and Xu Q. Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ Res 86 (2000) 434-440
22. Crook M.F., Newby A.C., and Southgate K.M. Expression of intercellular adhesion molecules in human saphenous veins. effects of inflammatory cytokines and neointima formation in culture. Atherosclerosis 150 (2000) 33-41
23. Jiang Z., Wu L., Miller B.L., Goldman D.R., Fernandez C.M., Abouhamze Z.S., et al. A novel vein graft model. adaptation to differential flow environments. Am J Physiol Heart Circ Physiol 286 (2004) H240-H245
24. Jiang Z., Berceli S.A., Pfahnl C.L., Wu L., Goldman D., Tao M., et al. Wall shear modulation of cytokines in early vein grafts. J Vasc Surg 40 (2004) 345-350
25. Dietrich H., Hu Y., Zou Y., Huemer U., Metzler B., Li C., et al. Rapid development of vein graft atheroma in ApoE-deficient mice. Am J Pathol 157 (2000) 659-669
26. Klyachkin M.L., Davies M.G., Kim J.H., Barber L., Dalen H., Svendsen E., et al. Postoperative reduction of high serum cholesterol concentrations and experimental vein bypass grafts. effect on the development of intimal hyperplasia and abnormal vasomotor function. J Thorac Cardiovasc Surg 108 (1994) 556-566
27. Davies M.G., Fulton G.J., Huynh T.T.T., Barber L., Svendsen E., and Hagen P.O. Combination therapy of cholesterol reduction and l-arginine supplementation controls accelerated vein graft atheroma. Ann Vasc Surg 13 (1999) 484-493
28. Brauner R., Laks H., Drinkwater D.C., Chaudhuri G., Shvarts O., Drake T., et al. Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg. 114 (1997) 53-63
29. Sakaguchi T., Asai T., Belov D., Okada M., Pinsky D.J., Schmidt A.M., et al. Influence of ischemic injury on vein graft remodeling. role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation. J Thorac Cardiovasc Surg 129 (2005) 129-137
30. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy. the PREVENT single-centre, randomized, controlled trial. Lancet 354 (1999) 1493-1498
31. Hu Y., Baker A.H., Zou Y., Newby A.C., and Xu Q. Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 21 (2001) 1275
32. Shi C., Patel A., Zhang D., Wang H., Carmeliet P., Reed G.L., et al. Plasminogen is not required for neointima formation in a mouse model of vein graft stenosis. Circ Res 84 (1999) 883-890
33. Torsney E., Mayr U., Zou Y., Thompson W.D., Hu Y., and Xu Q. Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. Circ Res 94 (2004) 1466-1473
34. Kim A.Y., Walinsky P.L., Kolodgie F.D., Bian C., Sperry J.L., Deming C.B., et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance implications for vein graft failure. Circ Res 90 (2002) 205-212
35. Channon K.M., Fulton G.J., Davies M.G., Peters K.G., Ezekowitz M.D., Hagen P.O., et al. Modulation of tissue factor protein expression in experimental venous bypass grafts. Arterioscler Thromb Vasc Biol 17 (1997) 1313-1319
36. Annex B.H., Davies M.G., Fulton G.J., Huynh T.T.T., Channon K.M., Ezekowitz M.D., et al. Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts. J Surg Res 80 (1998) 164-170
37. McCann R.L., Hagen P.O., and Fuchs J.C. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. Ann Surg 191 (1980) 238-243
38. Schachner T., Zou Y., Oberhuber A., Mairinger T., Tzankov A., Laufer G., et al. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 25 (2004) 585-590
39. Cambria R.P., Ivarsson B.L., Fallon J.T., and Abbott W.M. Heparin fails to suppress intimal proliferation in experimental vein grafts. Surgery 111 (1992) 424-429
40. Huynh T.T.T., Davies M.G., Trovato M.J., Barber L., Safi H.J., and Hagen P.O. Reduction of lipid peroxidation with intraoperative superoxide dismutase treatment decreases intimal hyperplasia in experimental vein grafts. J Surg Res 84 (1999) 223-232
41. Davies M.G., Dalen H., Barber L., Svendsen E., and Hagen P.O. Lazaroid therapy (methylaminochroman: U83836E) reduces vein graft intimal hyperplasia. J Surg Res 63 (1996) 128-136
42. Jeremy J.Y., Dashwood M.R., Timm M., Izzat M.B., Mehta D., Bryan A.J., et al. Nitric oxide synthase and adenylyl and guanylyl cyclase activity in porcine interposition vein grafts. Ann Thorac Surg 63 (1997) 470-476
43. Jeremy J.Y., Izzat M.B., Birkett S.D., Knight D.M., Bryan A.J., and Angelini G.D. Reduced prostacyclin and increased leukotriene B4 synthesis in porcine venous-arterial grafts. Ann Thorac Surg 61 (1996) 143-148
44. Onohara T., Okadome K., Yamamura S., Komori K., Ishii T., Odashiro T., et al. Impaired endothelial prostacyclin production of the canine vein graft in a poor distal runoff limb. Surgery 113 (1993) 700-708
45. Onohara T., Okadome K., Ishii T., Yamamura S., Komori K., and Sugimachi K. The reversibility of impaired prostacyclin production of the vein graft. J Surg Res 55 (1993) 344-350
46. Kown M.H., Yamaguchi A., Jahncke C.L., Miniati D., Murata S., Grunenfelder J., et al. L-Arginine polymers inhibit the development of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 121 (2001) 971-980
47. Chaux A., Ruan X.M., Fishbein M.C., Ouyang Y., Kaul S., Pass J.A., et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 115 (1998) 604-614
48. Davies M.G., Dalen H., Kim J., Barber L., Svendsen E., and Hagen P.O. Control of accelerated vein graft atheroma with the nitric oxide precursor. L-arginine. J Surg Res 59 (1995) 35-42
49. Shukla N., Angelini G.D., Ascione R., Talpahewa S., Capoun R., and Jeremy J.Y. Nitric oxide donating aspirins. novel drugs for the treatment of saphenous vein graft failure. Ann Thorac Surg. 75 (2003) 1437-1442
50. Porter K.E., Olojugba D.H., Masood I., Pemberton M., Bell P.R., and London N.J. Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 28 (1998) 695-701
51. Porter K.E., Dickinson T., and London N.J.M. Inhibition of neointima formation in an organ culture of human saphenous vein. a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition. J Vasc Surg 34 (2001) 548-554
52. Wan S., Yim A.P.C., Johnson J.L., Shukla N., Angelini G.D., Smith F.C.T., et al. The endothelin 1A receptor antagonist BSF 302146 is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. J Thorac Cardiovasc Surg 127 (2004) 1317-1322
53. Dashwood M.R., Mehta D., Izzat M.B., Timm M., Bryan A.J., Angelini G.D., et al. Distribution of endothelin-1 (ET) receptors (ETA and ETB) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis 137 (1998) 233-242
54. Levitzki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 65 (2005) 581-586
55. Francis S.E., Hunter S., Holt C.M., Gadsdon P.A., Rogers S., Duff G.W., et al. Release of platelet-derived growth factor activity from pig venous arterial grafts. J Thorac Cardiovasc Surg 108 (1994) 540-548
56. Sterpetti A.V., Cucina A., Lepidi S., Randone B., Corvino V., D'Angelo L.S., et al. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. Surgery 123 (1998) 461-469
57. Sterpetti A.V., Cucina A., Randone B., Palumbo R., Stipa F., Proietti P., et al. Growth factor production by arterial and vein grafts. relevance to coronary artery bypass grafting. Surgery 120 (1996) 460-467
58. Huang B., Dreyer T., Heidt M., Yu J.C., Philipp M., Hehrlein F.W., et al. Insulin and local growth factor PDGF induce intimal hyperplasia in bypass graft culture models of saphenous vein and internal mammary artery. Eur J Cardiothorac Surg 21 (2002) 1002-1008
59. Huynh T.T.T., Davies M.G., Barber L., Svendsen E., and Hagen P.O. Local inhibition of tyrosine kinase activity markedly attenuates the development of intimal hyperplasia in experimental vein grafts. J Surg Res 77 (1998) 104-111
60. Hu Y., Zou Y., Dietrich H., Wick G., and Xu Q. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation. 100 (1999) 861-868
61. Yuda A., Takai S., Jin D., Sawada Y., Nishimoto M., Matsuyama N., et al. Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins. Life Sci 68 (2000) 41-48
62. Daugherty A., and Cassis L. Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med. 14 (2004) 117-120
63. O'Donohoe M.K., Schwartz L.B., Radic Z.S., Mikat E.M., McCann R.L., and Hagen P.O. Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts. Ann Surg 214 (1991) 727-732
64. Tsikouris J.P., Suarez J.A., Simoni J.S., Ziska M., and Meyerrose G.E. Exploring the effects of ACE inhibitor tissue penetration on vascular inflammation following acute myocardial infarction. Coron Artery Dis 15 (2004) 211-217
65. Tsunemi K., Takai S., Nishimoto M., Yuda A., Jin D., Sakaguchi M., et al. Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins. J Thorac Cardiovasc Surg 124 (2002) 621-625
66. Fulton G.J., Davies M.G., Barber L., Svendsen E., and Hagen P.O. Localized versus systemic angiotensin II receptor inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor L158,809. Surgery 123 (1998) 218-227
67. Aguilera C.M., George S.J., Johnson J.L., and Newby A.C. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res 58 (2003) 679-688
68. Southgate K.M., Mehta D., Izzat M.B., Newby A.C., and Angelini G.D. Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 19 (1999) 1640-1649
69. Porter K.E., Loftus I.M., Peterson M., Bell P.R., London N.J., and Thompson M.M. Marimastat inhibits neointimal thickening in a model of human vein graft stenosis. Br J Surg 85 (1998) 1373-1377
70. Porter K.E., Thompson M.M., Loftus I.M., McDermott E., Jones L., Crowther M., et al. Production and inhibition of the gelatinolytic matrix metalloproteinases in a human model of vein graft stenosis. Eur J Vasc Endovasc Surg 17 (1999) 404-412
71. Werba J.P., Tremoli E., Massironi P., Camera M., Cannata A., Alamanni F., et al. Statins in coronary bypass surgery. rationale and clinical use. Ann Thorac Surg 76 (2003) 2132-2140
72. Porter K.E., Naik J., Turner N.A., Dickinson T., Thompson M.M., and London N.J.M. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J Vasc Surg 36 (2002) 150-157
73. Brauner R., Laks H., Drinkwater D.C., Chaudhuri G., Shvarts O., Drake T., et al. Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg. 114 (1997) 53-63
74. El-Sanadiki M.N., Cross K.S., Murray J.J., Schuman R.W., Mikat E., McCann R.L., et al. Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment. Ann Surg 212 (1990) 87-96
75. Davies M.G., Barber L., Dhanraj D.N., Gettys T.W., Ramkumar V., and Hagen P.O. The temporal sequence of G-protein expression in intimal hyperplasia. J Surg Res 63 (1996) 115-122
76. Fulton G.J., Barber L., Svendsen E., Hagen P.O., and Davies M.G. Oral monoterpene therapy (perillyl alcohol) reduces vein graft intimal hyperplasia. J Surg Res 69 (1997) 128-134
77. Saunders P.C., Pintucci G., Bizekis C.S., Sharony R., Hyman K.M., Saponara F., et al. Vein graft arterialization causes differential activation of mitogen-activated protein kinases. J Thorac Cardiovasc Surg 127 (2004) 1276
78. Yamashita A., Hanna A.K., Hirata S., Dardik A., and Sumpio B.A. Antisense basic fibroblast growth factor alters the time course of mitogen-activated protein kinase in arterialized vein graft remodeling. J Vasc Surg 37 (2003) 866-873
79. Suggs W.D., Olson S.C., Madnani D., Patel S., and Veith F. Antisense oligonucleotides to c-fos and c-jun inhibit intimal thickening in a rat vein graft model. Surgery 126 (1999) 443-449
80. Mannion J.D., Ormont M.L., Magno M.G., O'Brien J.E., Shi Y., and Zalewski A. Sustained reduction of neointima with c-myc antisense oligonucleotides in saphenous vein grafts. Ann Thorac Surg 66 (1998) 1948-1952
81. Shintani T., Sawa Y., Takahashi T., Matsumiya G., Matsuura N., Miyamoto Y., et al. Intraoperative transfection of vein grafts with the NFkappaB decoy in a canine aortocoronary bypass model. a strategy to attenuate intimal hyperplasia. Ann Thorac Surg 74 (2002) 1132-1138
82. Ehsan A., Mann M.J., Dell'Acqua G., and Dzau V.J. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy. J Thorac Cardiovasc Surg 121 (2001) 714-722
83. Schachner T., Zou Y., Oberhuber A., Tzankov A., Mairinger T., Laufer G., et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 77 (2004) 1580-1585
84. Schachner T., Oberhuber A., Zou Y., Tzankov A., Ott H., Laufer G., et al. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardiothorac Surg. 27 (2005) 302-306
85. Sousa J.E., Serruys P.W., and Costa M.A. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 107 (2003) 2274-2279
86. Sousa J.E., Serruys P.W., and Costa M.A. New frontiers in cardiology: drug-eluting stents: Part II. Circulation 107 (2003) 2383-2389